Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial

doi:10.3748/wjg.v18.i18.2203

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 18

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3402)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-8) series.

Item

Count

PDF

326

HTML

2753

Figures (1-3)

181

Tables (1-8)

142

Sum=3402

May 14, 2012 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. May 14, 2012; 18(18): 2203-2211
Published online May 14, 2012. doi: 10.3748/wjg.v18.i18.2203

Table 2 Characterization of the study population n (%)

	CG-casein	IG-soy	Total	P value
Demographic characteristics
Gender
Male	49 (61.2)	53 (66.2)	102 (63.8)	0.62¹
Female	31 (38.8)	27 (33.8)	58 (36.2)
Marital Status
Married	56 (70.0)	55 (68.7)	111 (69.4)	1.00¹
Single, widowed or divorced	24 (30.0)	25 (31.3)	49 (30.6)
Anthropometric data
Body mass index
< 25 kg/m²	40 (50.0)	43(53.8)	83 (51.9)	0.751¹
≥ 25 kg/m²	40 (50.0)	37(46.2)	77 (48.1)
Waist circumference
Adequate	43 (53.7)	46 (59.0)	89 (56.3)	0.525¹
Inadequate	37 (46.3)	32 (41.0)	69 (43.7)
Clinical data
Genotype
1	66 (88.0)	61 (79.2)	127 (83.5)	0.189¹
2/3	9 (12.0)	16 (20.8)	25 (16.5)
Necroinflammatory activity
A0	26 (41.3)	29 (46.8)	55 (44.0)	0.792¹
A1	26 (41.3)	22 (35.5)	48 (38.4)
A2 e A3	11 (17.4)	11 (17.7)	22 (17.6)
Stage of fibrosis
F0/F1/F2	35 (55.6)	40 (63.5)	75 (59.5)	0.468¹
F3/F4	28 (44.4)	23 (36.5)	51 (40.5)
Hepatic steatosis
Yes	24 (40.0)	19 (29.7)	43 (34.7)	0.260¹
No	36 (60.0)	45 (70.3)	81 (65.3)
HOMA-IR
< 3.0	55 (53.9)	47 (46.1)	102 (63.7)	0.25¹
≥ 3.0	25 (43.1)	33 (56.9)	58 (36.3)
Biochemical data	Median (iq r)	Median (iq r)
Glucose (mg/dL)	91.0 (14.2)	91.5 (14.2)		0.70²
HOMA-IR	2.35 (2.24)	2.26 (2.59)		0.99²
Triglycerides (mg/dL)	96.5 (60.2)	96.0 (67.2)		0.57²
Total cholesterol (mg/dL)	149.0 (49.7)	160.0 (44.0)		0.42²
HDL (mg/dL)	44.0 (14.2)	44.0 (15.5)		0.30²
LDL (mg/dL)	90.5 (40.7)	90.0 (43.0)		0.94²
AST (U/L)	59.5 (40.7)	52.0 (44.5)		0.14²
ALT (U/L)	76.5 (54.5)	73.5 (53.0)		0.38²
γGT (U/L)	102.0 (118.0)	87.0 (114.0)		0.71²
Alkaline phosphatase (U/L)	79.0 (33.5)	80.0 (53.2)		0.49²

¹Fisher’s exact test;

²Mann-Whitney; iq r: Interquartile range. n = 160. CG-casein: Control group-casein; IG-soy: Intervention group-soy; Adequate waist circumference: ≤ 80 cm for women and ≤ 94 cm for men. HOMA-IR: Homeostasis model assessment index of insulin resistance; HDL: High density lipoprotein; LDL: Low density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: Gamma glutamyl transferase.

Citation: Oliveira LP, Jesus RP, Boulhosa RS, Mendes CMC, Gnoatto MC, Lemaire DC, Toralles MBP, Cavalcante LN, Lyra AC, Lyra LG. Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial. World J Gastroenterol 2012; 18(18): 2203-2211
URL: https://www.wjgnet.com/1007-9327/full/v18/i18/2203.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i18.2203